← All peptides

Survodutide

GLP-1 / glucagon dual agonist. Metabolic research.

Route
SUBQ
Typical dose range
1.8 mg to 3.6 mg
Frequency
weekly
Half-life
5.41667 days
Cycle on / off (days)
84 / 28
Evidence grade
B

Reconstitution math

Open the pre-filled Survodutide reconstitution calculator to compute syringe units per dose.

Reported Side Effects of Survodutide

Effects below are summarised from peer-reviewed literature or regulatory labeling where it exists. Not medical advice. Individual responses vary.

  • Nausea, vomiting, and diarrhea, especially during dose titration DailyMed
  • Constipation and early satiety DailyMed
  • Injection-site reactions including redness and induration FDA label
  • Gallbladder-related events (cholelithiasis, cholecystitis) reported in pivotal trials NEJM
  • Risk of pancreatitis (discontinue if suspected) FDA label
  • Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2 FDA boxed warning

Compare Survodutide

How Survodutide stacks up against the peers most users consider.